Compare · CRWD vs ORPH
CRWD vs ORPH
Side-by-side comparison of CrowdStrike Holdings Inc. (CRWD) and Orphazyme A/S (ORPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRWD and ORPH operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- CRWD carries a market cap of $232.03B.
- CRWD has hit the wire 43 times in the past 4 weeks while ORPH has been quiet.
- CRWD has more recent analyst coverage (25 ratings vs 0 for ORPH).
- Company
- CrowdStrike Holdings Inc.
- Orphazyme A/S
- Price
- -
- -
- Market cap
- $232.03B
- -
- 1M return
- -7.35%
- -
- 1Y return
- +68.63%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 43
- 0
- Recent ratings
- 25
- 0
CrowdStrike Holdings Inc.
CrowdStrike Holdings, Inc. provides cloud-delivered solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. It offers 19 cloud modules on its Falcon platform through a software as a service subscription-based model that covers various security markets, such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. The company primarily sells its platform and cloud modules through its direct sales team. CrowdStrike Holdings, Inc. was incorporated in 2011 and is headquartered in Sunnyvale, California.
Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Latest CRWD
- PRESIDENT AND CEO Kurtz George sold $6,262,728 worth of shares (27,462 units at $228.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.38% to 7,225,647 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $582,471 worth of shares (2,538 units at $229.50) as part of a pre-agreed trading plan, decreasing direct ownership by 0.04% to 7,223,109 units (SEC Form 4)
- CrowdStrike Named One of the World’s 25 Best Workplaces for Second Consecutive Year
- CrowdStrike Named a Leader in the 2026 IDC MarketScape for Augmented Identity Security Solutions
- PRESIDENT AND CEO Kurtz George sold $4,447,090 worth of shares (20,000 units at $222.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.27% to 7,253,109 units (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $4,624,045 worth of shares (20,000 units at $231.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.27% to 7,273,109 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Podbere Burt W. sold $1,943,454 worth of shares (7,710 units at $252.07), decreasing direct ownership by 2% to 335,226 units (SEC Form 4) (for tax liability)
- PRESIDENT AND CEO Kurtz George sold $11,243,016 worth of shares (45,395 units at $247.67) as part of a pre-agreed trading plan, decreasing direct ownership by 0.62% to 7,296,109 units (SEC Form 4) to satisfy tax liability
- Director Gandhi Sameer K sold $3,442,423 worth of shares (14,000 units at $245.89) as part of a pre-agreed trading plan (SEC Form 4)
- PRESIDENT AND CEO Kurtz George sold $746,799 worth of shares (3,000 units at $248.93) as part of a pre-agreed trading plan, decreasing direct ownership by 0.04% to 7,293,109 units (SEC Form 4)
Latest ORPH
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 20-F filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form 6-K filed by Orphazyme A/S
- SEC Form NT 20-F filed by Orphazyme A/S